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Abstract—To determine whether Toxoplasma gondii infec-
tion could modify biological phenomena associated with
brain ischemia, we investigated the effect of permanent mid-
dle cerebral artery occlusion (MCAO) on neuronal survival,
inﬂammation and redox state in chronically infected mice.
Infected animals showed a 40% to 50% decrease of infarct
size compared with non-infected littermates 1, 4 and 14 days
after MCAO. The resistance of infected mice may be associ-
ated with increased basal levels of anti-inﬂammatory cyto-
kines and/or a marked reduction of the MCAO-related brain
induction of two pro-inﬂammatory cytokines, tumor necrosis
factor-alpha and interferon-gamma (IFN). In addition, poten-
tial anti-inﬂammatory/neuroprotective factors such as
nerve growth factor, suppressor of cytokine signaling-3, su-
peroxide dismutase activity, uncoupling protein-2 and gluta-
thione (GSH) were upregulated in the brain of infected mice.
Consistent with a role of GSH in central cytokine regulation,
GSH depletion by diethyl maleate inhibited Toxoplasma gon-
dii lesion resistance by increasing the proinﬂammatory cyto-
kine IFN brain levels. Overall, these ﬁndings indicate that
chronic toxoplasmosis decisively inﬂuences both the inﬂam-
matory molecular events and outcome of cerebral ischemia.
Key words: toxoplasmosis, cerebral ischemia, cytokines,
redox factors, rodent.
One of the possible biological consequences of infection is
a change of the redox status in both CNS and peripheral
tissues (Arsenijevic et al., 2001). Although both animal
models and clinical studies showed that infections promote
neuronal death following cerebral ischemic injury (Sacco,
2001; Emsley and Tyrrell, 2002), activation of the immune
system can also result in neuroprotection (Bordet et al.,
2000). In fact, the effect of infection on ischemic damage
may largely depend on the regulation of reactive oxygen
species by pro-inﬂammatory and anti-inﬂammatory cyto-
kines as well as by the main antioxidant state regulators,
namely superoxide dismutase (SOD) (Guegan et al., 1998;
Murakami et al., 1998), glutathione (GSH) (Nicholls and
Budd, 2000; Schulz et al., 2000; Droge, 2002), uncoupling
protein-2 (UCP2) (Arsenijevic et al., 2000b; Mattiasson et
al., 2003) and nerve growth factor (NGF) (Brodie, 1996;
Guegan et al., 1999; Villoslada et al., 2000). In addition,
the newly described suppressor of cytokine signaling
(SOCS) proteins are induced in peripheral and central
models of inﬂammation (Lebel et al., 2000; Bates et al.,
2001; Larsen and Ropke, 2002; Wang and Campbell,
2002; Huang et al., 2003; Park et al., 2003; Jo et al., 2005).
SOCS possibly interact with cellular redox determinants
(Park et al., 2003) and transgenic SOCS expression has
been shown to inhibit inﬂammation and apoptosis following
lipopolysaccharide (LPS) injection (Jo et al., 2005).
Chronic murine toxoplasmosis may be of particular
interest in the study of infection-related effects on brain
ischemia since it is associated with a tissue-speciﬁc regu-
lation of the oxidative state (Arsenijevic et al., 2001) as well
as activation of pro-inﬂammatory cytokines such as tumor
necrosis factor-alpha (TNF), interferon-gamma (IFN)
and interleukin-2 (IL-2), but also anti-inﬂammatory cyto-
kines such as interleukin-10 (IL-10) (Arsenijevic et al.,
1997, 1998). Some of these cytokines are known to en-
hance neurodegeneration following ischemia (Arsenijevic
et al., 2006). In order to determine how chronic infection
inﬂuences the main biological phenomena associated with
acute cerebral ischemia, the present study explores the
impact of chronic Toxoplasma gondii infection on brain
ischemic injury and inﬂammatory/antioxidant processes in-
duced by permanent middle cerebral artery occlusion
(MCAO).
EXPERIMENTAL PROCEDURES
All procedures were approved by the Veterinary Ofﬁce of the
Canton of Zurich Health Directorate and the Veterinary Ofﬁce of
Geneva in accordance with the Swiss Animal Care Guidelines. All
efforts were made to minimize the number of animals used in this
study and every effort was taken to reduce any suffering.
1 Equal ﬁrst authors.
*Corresponding author. Tel: 41-79-501-52-83; fax: 41-26-300-97-34.
E-mail address: denis.arsenijevic@unifr.ch (D. Arsenijevic).
Abbreviations: cDNA, complementary DNA; DEM, diethyl maleate;
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GSH, glutathi-
one; IFN, interferon-gamma; IL-2, interleukin-2; IL-10, interleukin-10;
LPS, lipopolysaccharide; MCAO, middle cerebral artery occlusion; NGF,
nerve growth factor; SOCS, suppressor of cytokine signaling; SOCS-3,
suppressor of cytokine signaling-3; SOD, superoxide dismutase; TNF,
tumor necrosis factor-alpha; TUNEL, terminal deoxynucleotidyl trans-
ferase biotin-dUTP nick end labeling; UCP2, uncoupling protein-2.
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Published in "Neuroscience 150(3): 537-546 , 2007"
which should be cited to refer to this work.
Mice and diets
Male Swiss Webster mice of 4 months of age from Charles River
Laboratories (Wilmington, MA, USA) were used. Mice were chron-
ically infected by i.p. injection of 10 cysts of Toxoplasma gondii
(Me49 strain obtained from Dr A. Hemphill, University of Bern,
Switzerland) (Arsenijevic et al., 1997). Less than 5% of mice died
due to infection during weeks 2 and 3. After this time point all
infected mice survived. Acute infection with Toxoplasma gondii
results in anorexia and body weight loss (Arsenijevic et al., 1997).
We followed infected mice body weight and food intake 7 days
before infection and up to 28 days (chronic phase) after infection
(n10). In the chronic phase of infection, some of these mice may
show a partial weight regain (50%) or no weight regain (50%)
(Arsenijevic et al., 1997). For all experiments, we used only the
latter type of mice since these animals had higher basal brain
cytokine levels and were expected to maximally respond to a new
inﬂammation (Arsenijevic et al., 1998). A group of non-infected
mice (n18) was chronically underfed to mimic the food intake
level of infected mice from days 1–28. This group was used to
determine: 1) if the reduced food intake of the infected mice may
inﬂuence basal brain GSH levels (n6); 2) the effect of under-
feeding on brain GSH levels after MCAO (n6) and 3) the effect
of underfeeding on ischemic lesion size (n6). All mice were
individually weighed and food intake was measured daily. For the
MCAO study, infected and non-infected mice with and without
MCAO (n18 mice per group) were monitored daily from 7 days
prior to and up until 3 days after operation. Daily food intake
(g/mouse/day) and body weight changes after MCAO were mea-
sured, and food intake changes after MCAO were calculated as a
percentage of pre-ischemia average food intake for each mouse
group.
Histology of infected brains compared with
non-infected controls
Histological analysis was performed in infected (28 days following
infection) (n4) and non-infected control brains (n4) prior to
MCAO. Brain slices (20 m) were stained with hematoxylin and
eosin for histological identiﬁcation of Toxoplasma gondii cysts and
inﬁltrating immune cells (Frenkel and Escajadillo, 1987; Arseni-
jevic et al., 2007a). Detection of apoptosis in the brain of chroni-
cally infected mice was made using terminal deoxynucleotidyl
transferase biotin-dUTP nick end labeling (TUNEL) labeling as
previously described (de Bilbao et al., 2000). The suppressor of
cytokine signaling-3 (SOCS-3) mRNA expression was determined
by in situ hybridization in the brains of these mice (n6 per group).
Riboprobe preparation and in situ hybridization histochemistry
were kindly performed by Dr S. Rivest (Laval University, Canada).
The rat SOCS-3 complementary DNA (cDNA) fragment that was
initially inserted in a pEF-FLAG-1 vector (provided by Dr. Doug
Hilton, The Walter and Eliza Hall Institute of Medical Research,
Melbourne, Australia) was extracted with XbaI and reinserted into
a pCRII (Invitrogen, Carlsbad, CA, USA). The new construct was
then linearized with XhoI. 35S-UTP was used to label the probe
(for the complete in situ hybridization protocol conditions see
reference by Lebel et al., 2000).
Induction of permanent focal cerebral ischemia
and volume of the infarct
Mice were operated 28 days after infection, when their body
weight and food intake had stabilized (Arsenijevic et al., 1998). We
performed permanent MCAO in infected and non-infected control
mice (n6 for each group and post-MCAO time) as described in
details elsewhere (de Bilbao et al., 2000). All mice survived and
showed infarction after MCAO. One day, 4 days and 14 days later,
the animals were perfused through the ascending aorta with a
solution of paraformaldehyde 4% in phosphate-buffered saline
(PBS, pH 7.35). Brains were removed and processed for parafﬁn
embedding. Sections (7 m) of the whole infarct area were cut on
slides pretreated with 3-aminopropyltriethoxy-silane (Sigma, MO,
USA), counterstained with Cresyl Violet for the histological iden-
tiﬁcation of the nuclear boundaries and peri-infarct areas and
mounted in Eukitt. For each animal, quantiﬁcation of the infarcted
area was performed on the Cresyl Violet–stained sections at ﬁve
representative levels throughout the rostro-caudal extent of the
lesion (A 0.26, 0.22, 0.40, 0.70 and 1.2–4 mm relative to
Bregma) (Franklin and Paxinos, 1997). The rostro-caudal extent
of the infarct was the same in both groups of mice. The infarcted
area of each section was calculated by the subtraction of healthy
tissue areas of the contralateral to the ipsilateral side of the
section in order to compensate for the effect of brain edema
(Guegan et al., 1998) using a computer-assisted image analyzing
system (Software Morphometry, Samba 2005 TITN, Alcatel). Vol-
umes of infarct (mm3) were calculated for each animal after inte-
gration of areas with the distance between each level (de Bilbao
et al., 2000).
To evaluate whether local alterations in cerebral vascular
anatomy contribute to different susceptibility to injury in infected
mice, an additional series of ﬁve non-infected and ﬁve infected
mice were killed on day 1 after ischemia. Cerebral vasculature
was studied in non-infected and infected mice (non-operated and
on day 1 after ischemia) after intracardial perfusion of a mixture of
an equal proportion of gelatinous water (5%) and China ink (Sen-
nelier, France) warmed at 40 °C (1 ml). Brains were removed and
immersed for 24 h in 4% paraformaldehyde at 4 °C (Chen et al.,
2005). Cerebral vasculature was observed with a Zeiss stereo
zoom microscope. The absence of cerebral blood ﬂow in the
infarct area was assessed visually and by transcranial measure-
ments of cerebral blood ﬂow that were made using laser Doppler
ﬂowmetry (Oxford Optronix Ltd., UK) just before and after MCAO.
Animals were placed under a stereotactic head frame and then a
ﬁne needle probe (MNP110XP, 0.48 mm diameter) was lowered
onto the temporal bone surface 0.5–1 mm dorsal to the opening
giving access to the MCA and wetted with a small amount of
physiological saline.
Physiological parameters
Physiological parameters including arterial blood pressure (Kent
mouse tail blood pressure system RTBP2000, Kent Scientiﬁc
Corporation, Torrington, USA), plasma glucose (using Roche Glu-
cotrend Active, Rotkreuz, Switzerland) and hematocrit were mea-
sured daily (n5 for each type of mice) before MCAO and on day
1 and day 4 after injury. During surgery, mice were placed on a
warm mat and rectal temperature was measured. During the
operation, all mice had a body temperature of 38 °C.
Northern blot for UCP2 mRNA
Infected and non-infected mice subjected or not to ischemia (1 day
post-MCAO) (n6 mice per group) were anesthetized i.p. with
xylazine (20 mg/kg)/ketamine (100 mg/kg) in 0.9% NaCl (100 l/
10 g body weight). They were intracardially perfused without delay
with ice-cold isotonic saline. At the end of the perfusion the whole
brains were quickly dissected out and frozen. Total RNA was
prepared as described before (Arsenijevic et al., 1997). Northern
blot analyses were performed using the mouse UCP2 or glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) cDNA labeled
with 32P under standard conditions. A similar amount of total RNA
(20 g) was used in every lane.
Cytokines and NGF levels in brain
We measured TNF, IFN, IL-10, IL-2 and NGF in the brain of
infected and non-infected mice subjected or not to ischemia (1 day
post-MCAO; n6 mice per group). Brains were analyzed 1 day
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after ischemia since it is well established that cytokines return to
basal levels after this time point (Guegan et al., 1998). They were
aseptically removed, immediately placed in dry ice and then put in
CHAPS solution and homogenized (Arsenijevic et al., 2000a). The
supernatant was collected and frozen at 20 °C. TNF, IFN,
IL-10, and IL-2 were measured by using immunoassay kits from
Amersham (Switzerland) (Arsenijevic et al., 2006). An immunoas-
say kit was also used to determine NGF (Catalys, Switzerland)
(Arsenijevic et al., 2006).
SOD activity
We investigated SOD activity using a biochemical assay (1 day
post-MCAO; n6 mice per group) (Ewing and Janero, 1995).
Brains were homogenized in phosphate-buffered saline and fro-
zen immediately in liquid nitrogen. Aliquots of brain supernatants
were processed as previously described (Ewing and Janero,
1995). Brain supernatants were added (25 l) to a 125 l solution
containing 50 mM phosphate buffer (pH 7.4, 0.1 mM EDTA, 50 M
NBT, 78 M NADH). To start the reaction, 25 l of 3.3 M PMS
phenazine methosulfate (Sigma) (ﬁnal concentration) was added
and the absorbance at 560 nm was measured continuously using
a microplate reader (DynaTech MR5000). The readings were
every minute for 10 min. The ﬁrst 5 min were used to determine
the rate of superoxide production by the samples.
GSH levels
Tissues were collected from infected (1, 3, 7, 14 and 28 days
post-infection) and non-infected control mice (n6 mice per
group). The consequences of MCAO for brain GSH levels were
also determined in both types of mice 1 day post-ischemia (n6
for each group). Tissues were homogenized in phosphate buffer
(50 mM, pH 7.4). Total GSH levels were measured using a
method based on the formation of a chromophoric product result-
ing from the reaction of 5,5=-dithiobis-(2-nitrobenzoic acid) (DTNB,
Sigma) and GSH (Sigma) (de Bilbao et al., 2004). The absorbance
was immediately measured at 412 nm. GSH contents were cal-
culated by using a calibration curve established with standard
samples.
To test whether elevated brain GSH levels in infected mice
1) were involved in the lack of cytokine induction 1 day after
MCAO and 2) may inﬂuence lesion size response after ischemia,
GSH was depleted by a s.c. injection of diethyl maleate (DEM)
(24 l/ 30 g body weight and was made up to 300 l with saline)
(Pileblad and Magnusson, 1990). To determine if DEM depleted
brain GSH, non-infected (n3) and infected mice (n3) were
treated with DEM and killed 2 h later and GSH in brain was
measured as described above. To determine whether GSH de-
pletion may alter TNF and IFN levels 1 day after MCAO, in-
fected (n4) and non-infected mice (n4) were treated with DEM,
underwent MCAO 2 h later and were killed 1 day post-ischemia.
Estimates of brain cytokine levels were obtained as described
above. For all experiments, mice treated with saline were used as
controls for the DEM groups.
Brains of 28-day infected mice (see Histology section) were
stained for GSH with the ﬂuorescent histochemical dye phthaldi-
aldehyde (10 mM) and then processed for microglia immunohis-
tochemistry using the anti-Iba-1 antibody (1 mg/ml, from Dr. Y.
Imai, National Center of Neurology and Psychiatry, Japan) which
was detected by the ﬂuorescent goat-anti-rabbit immunoglobulin
Alexa Fluor 568 (Molecular Probes) (de Bilbao et al., 2004). Since
we have previously shown that chronic toxoplasmosis results in an
increased brain expression of UCP2 mRNA which is speciﬁc for
microglia associated with inﬂammatory loci (Arsenijevic et al.,
2007), we also explored whether there was an association be-
tween GSH and UCP2 in this cell type. Mounted brain sections
were immunostained for GSH using rabbit polyclonal anti-GSH
(1/10 dilution provided by Prof. Ottersen, University of Oslo, Nor-
way) which was revealed by ABC kit peroxidase and subsequently
processed for in situ hybridization using a rat UCP2 probe (de
Bilbao et al., 2004).
Data analyses
All data are presented as meansS.E. Statistical analyses were
performed using Kruskal-Wallis non-parametric test. P values of
less than 0.05 were considered signiﬁcant.
RESULTS
Physiological parameters before and after MCAO
Arterial pressure, plasma glucose and hematocrit levels
before and after MCAO on day 1 and day 4 were not
signiﬁcantly different between non-infected and infected
mice at a given time point as shown in Table 1. After
MCAO, both non-infected and infected mice showed an
absence of cerebral blood ﬂow in the infarct area.
Brain histology and SOCS-3 mRNA induction
in infected mice
Unlike non-infected mice, the brains of the infected mice
showed many randomly located inﬂammatory loci (includ-
ing neutrophils, macrophages/monocytes and lympho-
cytes) 28 days after infection. These loci were not colocal-
ized with intact Toxoplasma gondii cysts (Fig. 1A, B) and
also occurred around blood vessels, but not within the
vessels’ walls (Fig. 1C). There was no evidence of neuro-
nal apoptosis as determined by TUNEL labeling in these
mice (data not shown). In situ hybridization showed
SOCS-3 basal expression mainly in the hypothalamic re-
gion (Fig. 1D) (Lebel et al., 2000). Following infection,
SOCS-3 mRNA labeling was randomly induced throughout
the cerebral cortex as well as in areas associated with
brain immune cell inﬁltration and blood vessels (Fig. 1D).
This expression was associated with neurons, microglia
and inﬁltrating phagocytes as previously described (data
not shown) (Lebel et al., 2000).
Ischemic brain injury is reduced in Toxoplasma
gondii infected mice
One day, 4 days and 14 days after MCAO, infarct volume
was decreased by 42%, 50% and 48% respectively in
Table 1. Physiological parameters before and after MCAO in non-
infected and infected mice
Group and treatment 1 Day
before MCAO
D1 after
MCAO
D4 after
MCAO
Hematocrit (%)
Non-infected 424 445 455
Infected 484 504 514
Plasma glucose (mmol/L)
Non-infected 8.20.2 7.90.3 8.15
Infected 7.70.3 7.60.2 7.84
Arterial pressure (mm Hg)
Non-infected 948 968 955
Infected 10512 989 1016
Data are meansS.E.M. of 5 animals per group. See text for details.
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Toxoplasma gondii infected mice when compared with
non-infected control mice (P0.01) (Fig. 1E, F), suggest-
ing that chronic infection with Toxoplasma gondii may
protect neocortical areas from ischemic damage.
Transient hyperphagia occurs early in Toxoplasma
gondii–infected mice in response to MCAO
On the day of lesion, MCAO resulted in a signiﬁcant re-
duction of food intake in both infected and non-infected
control mice when compared with their pre-MCAO basal
food intakes (260.5% and 390.7% respectively,
n18, P0.01). The day after ischemia, both non-infected
and infected mice started to regain appetite. From this time
point, infected mice increased food intake more rapidly
than the non-infected group (30.2% and 282%,
respectively, n18, P0.01). Infected mice showed signif-
icantly enhanced hyperphagia on days 2 and 3 postisch-
emia compared with their non-operated controls (281.2%
and 10.2% respectively, n18, P0.01). Body weight
loss induced by ischemia followed a similar temporal pat-
tern to that of food intake indicating that Toxoplasma
gondii–infected mice had attenuated negative energy bal-
ance in response to MCAO.
Brain speciﬁc alterations in GSH levels
due to infection
There was a 45% decrease in brain GSH levels on day 7
postinfection when compared with non-infected control
Fig. 1. Brain histology, in situ hybridization for SOCS-3 mRNA expression and brain infarct size in Toxoplasma gondii infected mice. (A–C) Coronal
cross-sections of a Toxoplasma gondii–infected (for 28 days) mouse brain stained with hematoxylin and eosin (scale bar15 m). Note that infection
resulted in inﬂammatory loci found in brain tissue (A) (thin black arrow) and in association with blood vessels (B, C) (thin black arrows). Note also that
the presence of Toxoplasma cysts was not associated with inﬂammatory loci (B, thick arrow). (D) Representative in situ hybridization for SOCS-3
mRNA in non-infected control (Cont) and infected mice (Tox) brains (scale bar120 m). SOCS-3 mRNA basal expression was found in particular
in hypothalamic region. Twenty-eight days following infection, SOCS-3 mRNA expression was randomly located and induced throughout the brain of
infected mice in particular in the cortical area (Tox) (n4 for each group). The right column shows a higher magniﬁcation of selected areas speciﬁc
for SOCS-3 mRNA expression in infected brains. SOCS-3 mRNA was associated with microglia/inﬁltrated immune cells (thick arrow) and blood
vessels (thin arrow). Cells are visualized with Thionin staining and SOCS-3 silver grains are black (scale bars15 m). (E, F) Effect of Toxoplasma
gondii infection on infarct size. (E) Representative coronal sections showing ischemic lesion size 4 days after MCAO in control (Cont MCAO) and
chronically infected mice (Tox MCAO). Sections were stained with Cresyl Violet. The surrounded areas denote the size of the ischemic area (scale
bars120 m). (F) Infarct brain volumes were reduced in infected mice (Tox) at 1, 4 and 14 days after MCAO compared with non-infected mice (Cont).
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mice (P0.05). On day 14, as mice started to regain
appetite, there was a progressive increase in brain GSH
levels in infected mice (P0.001) up to 28 days after
infection (P0.001) (Fig. 2A). The increase in GSH in the
brains of 28-day infected mice was associated with a spe-
ciﬁc increase in microglia (Fig. 2B, C); only microglia with
elevated UCP2 mRNA levels showed GSH labeling (Fig.
2D, E). In non-infected control mice, MCAO resulted in
a 80% decrease of brain GSH levels (from 0.52
0.02 nmol/mg tissue to 2.600.18 nmol/mg tissue)
(P0.001) (Fig. 3A). Interestingly, this decrease due to
ischemia was only 11% in infected animals (from 4.60
0.80–4.110.31 nmol/mg tissue) (P0.01). In addition,
GSH brain content in infected animals having undergone
MCAO was signiﬁcantly higher compared with non-in-
fected MCAO animals (P0.001) (Fig. 3A). Chronically
underfed non-infected mice did not show altered brain
GSH levels compared with non-infected controls (2.47
0.19 versus 2.600.07 nmol/mg tissue) (Fig. 3A) suggest-
ing that anorexia does not explain the increased brain GSH
levels in infected mice. Although 1 day after ischemia,
GSH levels were reduced in the chronically underfed non-
infected mice, this decrease was signiﬁcantly less pro-
nounced compared with the non-infected control group
(P0.01) (Fig. 3A). This was associated with a reduced
infarct size in the chronically underfed group compared
with the non-infected control group (15.00.9 mm3 and
19.31.1 mm3, respectively, n6 mice, P0.05). Al-
Brain GSH
0
2
4
6
Co
nt
Da
y 
1
Da
y
4
Da
y
14
Da
y 
7
Da
y
28
n
m
o
l/
m
g
 t
is
s
u
e
*
***
***
2B 2C
2D 2E
2A
Fig. 2. Changes in brain GSH levels from day 1 to day 28 following murine Toxoplasma gondii infection. (A) Toxoplasmosis resulted in a slight
reduction in brain GSH levels on day 7. From day 14 to day 28 after infection, GSH was signiﬁcantly increased in the brain of infected mice compared
with non-infected control mice (Cont). Values (nmol/mg tissue) are presented as meanS.E. (* P0.05, *** P0.001, comparison to saline control).
Each group represents six mice. (B) GSH (ﬂuorescent staining, white arrow) is speciﬁcally increased in microglia in infected mice (red, white arrow)
(C). Only microglia cells that have increased UCP2 mRNA (E, black arrow) show an increase in GSH (immunohistochemical detection, orange, black
arrow) (D). Scale bars15 m (B, C, D); 7.5 m (E). For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web
version of this article.
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though a contributing effect cannot be excluded, the
underfeeding effect on reduced lesion size could not
totally explain the much greater reduction of infarct size
observed in the infected mice (10.20.4 mm3) (Fig. 1F)
(P0.05).
Infection increases brain SOD activity
SOD activity (Fig. 3B) was higher in the brains of in-
fected mice (14.21.2 units/mg protein) compared with
non-infected mice (10.20.8 units/mg protein)
(P0.01). This difference did not persist 1 day after
MCAO (Fig. 3B) as SOD activities were similarly in-
creased in both groups (17.21.5 and 15.11.1
units/mg protein respectively).
Upregulation of brain UCP2 mRNA levels in infected
mice after ischemia
Toxoplasmosis resulted in a 76% increase in brain UCP2/
GAPDH mRNA ratio compared with non-infected mice
(2.30.2 versus 1.30.1) (P0.01) (Fig. 3C). One day post-
MCAO, there was a 62% increase in UCP2/GADPH mRNA
ratio in infected mice compared with MCAO non-infected
mice (3.40.2 versus 2.10.2) (P0.001) (Fig. 3C).
Infection does not result in enhanced cytokine
levels after MCAO
Basal levels of proinﬂammatory cytokines (TNF, IL-2,
IFN) were increased in Toxoplasma gondii infected mice
on day 28 postinfection compared with non-infected con-
trols (P0.001) (Table 2). One day post-MCAO, infected
mice had higher TNF, IL-2 and IFN levels compared
with MCAO non-infected animals (P0.001). However,
these higher levels did not signiﬁcantly differ from those
observed in infected mice not subjected to ischemia. This
sharply contrasts with the results obtained in non-infected
mice which showed a marked induction of cytokine levels
1 day post-MCAO compared with non-operated animals.
Infected mice also had signiﬁcantly higher brain levels of
IL-10 and NGF compared with non-infected control mice
(P0.001) (Table 2). NGF and IL-10 signiﬁcantly in-
creased in non-infected mice that underwent MCAO
(P0.001); this induction was not observed in infected
mice suggesting an attenuated immune response in the
brains of infected mice (Table 2). Following MCAO, NGF
levels in infected animals were doubled compared with
non-infected controls (P0.001). This was not the case for
IL-10 suggesting that NGF may be a more important anti-
inﬂammatory agent in infected mice.
Fig. 3. Brain GSH, brain SOD activity and brain UCP2 mRNA expres-
sion. (A) One day after MCAO, we observed a reduction in brain GSH
levels in non-infected mice (Cont MCAO) compared with their non-
operated controls (Cont). After MCAO, brain levels of GSH in infected
mice were markedly elevated compared with non-infected animals
(Cont MCAO). Underfeeding (Ufc) results in no change in brain GSH
levels compared with control mice (Cont). One day after MCAO, GSH
level in underfed mice (Ufc MCAO) was reduced, however this reduc-
tion was less than that found in Cont MCAO mice. (B) Brain SOD
activity was increased during chronic infection (Tox) when compared
with non-infected animals (Cont). One day post-MCAO, SOD activities
were similarly increased in both groups compared with non-infected
controls (Cont). (C) Brain UCP2 mRNA expression was increased
following infection (Tox) compared with non-infected controls (Cont).
MCAO increased brain UCP2 mRNA levels in both infected and non-
infected mice, but levels were higher in the former group. Values are
presented as meanS.E. for the various groups. Each group repre-
sents six mice. * Indicates the statistical comparison with non-infected
controls (Cont), a indicates the statistical comparison between Tox and
Ufc mice, b indicates the statistical comparison between Tox MCAO
and Cont MCAO mice, c indicates the statistical comparison between
Tox and Tox MCAO mice, & indicates comparison between Cont
MCAO and Ufc MCAO (* P0.05, *** P0.001, ** P0.01,
*** P0.001, a P0.001, b P0.001, c P0.05, & P0.01).
Table 2. Basal and one day post-MCAO levels of brain TNF, IFN,
IL-2, IL-10 and NGF in non-infected and infected mice
Cont Cont MCAO Tox Tox MCAO
TNF pg/ml 1004 80012*** 99351*** 109350a
IFN pg/ml 252 1754*** 3308*** 3589a
IL-2 pg/ml 442 75023*** 162264*** 180461a
IL-10 pg/ml 242 49238*** 50440*** 56019
NGF pg/ml 403 30012*** 60022*** 62420a
Values (pg/ml tissue) are presented as meanS.E.
* Indicates statistical comparison with non-infected animals (Cont)
(*** P0.001). Each group included six mice. See text for details.
a Indicates statistical comparison between Tox MCAO and Cont
MCAO mice (a P  0.001). Each group included six mice. See text for
details.
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Depletion of brain GSH by DEM reversed neuroprotec-
tion by increasing lesion size and central IFN levels after
MCAO in infected mice.
Brain GSH levels in both non-infected and infected
mice were markedly decreased 2 h after an s.c. injection of
DEM as seen in Fig. 4A. One day after ischemia (Fig. 4B),
brain GSH levels were further reduced by DEM when
compared with non-treated MCAO groups. This reduction
was associated with an increased lesion size in infected
mice when compared with infected mice not treated with
DEM (22.21.7 mm3 versus 12.80.5 mm3, n6 per
group, P0.01). Non-infected mice also showed an in-
crease in lesion size when treated with DEM (15.8
1.5 mm3 for saline versus 20.31.0 mm3 for DEM, n6
per group, P0.05). After ischemia, DEM treatment re-
sulted in induction of central IFN levels but not TNF in
both types of mice (Fig. 4C, D). Note that, consistent with
the known transitory effect of DEM on GSH levels (Gupta
et al., 2000), GSH returned to basal levels 24 h after DEM
treatment in the absence of ischemic damage in both
infected and non-infected mice (Fig. 4C, D).
DISCUSSION
This study revealed a marked resistance of Toxoplasma
gondii–infected mice to acute cerebral ischemia character-
ized by a marked decrease of infarct size one, and 4 but
also 14 days post-MCAO. The reverse effect of DEM on
brain infarct size implies that GSH up-regulation may play
a pivotal role in the observed ischemic resistance. Our
results make it also possible to propose additional biolog-
ical mechanisms surrounding this phenomenon, such as
marked differences in pre- and/or post-ischemic cytokine
status as well as pre- and/or post-ischemic GSH, SOCS-3
mRNA and UCP2 mRNA levels in infected compared with
non-infected mice.
Following the acute phase of toxoplasmosis, the ini-
tially produced pro-inﬂammatory cytokines will subse-
quently induce a counter-regulatory anti-inﬂammatory re-
sponse (Arsenijevic et al., 1997). During the chronic phase
of infection, apart from the role that the adaptive speciﬁc
immune systems (CD4, CD8 T cell activation) could play,
the consequence of a second inﬂammation caused by
Fig. 4. GSH, TNF and IFN were measured in non-infected and infected mice after ischemia; 2 h prior to MCAO, mice were treated with DEM (or
saline). (A) DEM signiﬁcantly reduced brain GSH in non-infected and infected mice 2 h after treatment. (B) Twenty-four hours after ischemia, DEM
signiﬁcantly reduced brain GSH levels in infected and non-infected mice. Note that, consistent with the known transitory effect of DEM on GSH levels
(Gupta et al., 2000), GSH returned to basal levels 24 h after DEM treatment in the absence of ischemic damage in both infected and non-infected mice.
(C, D) DEM did not signiﬁcantly alter brain TNF (C) but signiﬁcantly increased brain IFN levels (D) 24 h after ischemia. Data are meansS.E. of
three to ﬁve animals per group. * P0.001, comparison with saline controls; a P0.001, comparison with MCAO controls.
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cerebral ischemia may be determined by the balance be-
tween these two antagonistic systems. The basal up-reg-
ulation of antioxidant molecules such as GSH, SOD,
UCP2, SOCS-3 mRNA and anti-inﬂammatory cytokines
NGF and IL-10 may represent the two ﬁrst lines of defense
against ischemic damage in infected mice. One could pos-
tulate that the observed changes in redox status may be a
simple epiphenomenon of the underfeeding observed in
the chronically infected mice. In fact, it has been shown
that underfeeding may result in protection from cerebral
injury by modifying redox status (Yu and Mattson, 1999).
Our ﬁndings show that both the steady increase of brain
GSH levels by day 7 to day 28 post-infection as well as the
brain resistance to ischemia are speciﬁc to Toxoplasma
gondii infection and did not depend on energy intake.
Actually, although we did ﬁnd that post-ischemic GSH was
partially dependent on energy intake, this component rep-
resented only 13% of the post-ischemic GSH levels of
infected mice. We also show that energy intake does in-
ﬂuence lesion size, but alone cannot account for the de-
gree of resistance observed in infected animals. A possible
causal relationship between redox status and cytokine
production has been previously suggested in that in-
creased basal GSH levels and SOD activity may result
from high NGF levels (Guegan et al., 1998, 1999; de
Bilbao et al., 2004; Arsenijevic et al., 2006). Consistent
with their possible role in neuroprotection (Guegan et al.,
1999; Mattiasson et al., 2003), the differences in GSH,
UCP2 mRNA and NGF levels persisted between infected
and non-infected mice after MCAO. In the absence of a
speciﬁc antibody for brain UCP2, it was not possible to
assess the impact of UCP2 mRNA changes on protein
levels. However, previous data using UCP2 transgenic and
UCP2 KO mice have shown that UCP2 plays a central role
in brain neuroprotection following ischemia (Mattiasson et
al., 2003; de Bilbao et al., 2004).
An additional molecular mechanism involved in this
context may involve the absence of pro-inﬂammatory cy-
tokine induction observed in infected mice after ischemia.
This phenomenon could be partly due to the already ele-
vated basal levels of these cytokines in the brains of these
mice (i.e. counter-regulatory mechanisms). Although one
could argue that this ﬁnding might reﬂect the presence of a
threshold in cytokine levels reached in Toxoplasma-in-
fected mice, this is an unlikely scenario since we have
previously demonstrated that an i.p. injection of LPS led to
a marked upregulation of pro-inﬂammatory cytokines in
these mice (Arsenijevic et al., 1998). Importantly, infected
mice showed feeding behavior concordant with the relative
stunting of brain cytokine response after ischemia. In fact,
transient hyperphagia started earlier in infected mice com-
pared with non-infected mice after MCAO. This is consis-
tent with the attenuated post-ischemic induction of anorec-
tic cytokines (TNF, IFN) in the brain.
In agreement with previous contributions, our data sug-
gest that both SOCS-3 and GSH are plausible candidate
molecules for the regulation of secondary inﬂammatory
response and cytokine production in Toxoplasma gondii–
infected mice (Bjorkbaek et al., 1999; Auerhammer and
Melmed, 2001; Park et al., 2003). The absence of pro-
inﬂammatory cytokine induction could be partly due to the
parallel elevation of the SOCS-3 mRNA after infection. The
SOCS-3 is a potent inhibitor of cytokine signaling and its
transgenic over-expression may inhibit inﬂammation and
associated apoptosis in vivo (Auerhammer and Melmed,
2001; Jo et al., 2005). Accordingly, although infected mice
had elevated basal pro-inﬂammatory cytokine levels (i.e.
TNF, IFN and IL-2) (Eizenberg et al., 1995; Bate et al.,
2006; Lee et al., 2006; Yu et al., 2006), there was no
evidence of neuronal apoptosis in their brain tissue. A key
role for GSH is suggested by the fact that the decreased
infarct size in MCAO mice chronically infected is no longer
observed when brain GSH levels have been depleted by
DEM treatment. This phenomenon was speciﬁcally asso-
ciated with the central up-regulation of pro-inﬂammatory
IFN but not TNF in response to MCAO. Previous studies
have also shown that DEM may not have a marked effect
on TNF induction in response to an inﬂammatory response
(Kang et al., 1999; Wang et al., 1999). Further work is
needed to get a better understanding of the complex inter-
actions of molecules regulating the inﬂammatory response
in this context. As recently proposed, the observed ele-
vated basal SOCS-3 and GSH levels could act synergisti-
cally as GSH can interact in SOCS-3 pathways to inhibit
cytokines (Cisowski et al., 2002).
Besides its direct effect against oxidative stress, GSH
may also act via the suppression of glia-mediated inﬂam-
mation (Wang et al., 2006). In the same line with this idea,
our contributions have shown that both UCP2 and SOCS-3
mRNA levels in brains infected with Toxoplasma gondii
were elevated in microglia (Arsenijevic et al., 2007a). Al-
though we cannot exclude a possible participation of inﬁl-
trated leukocytes, our evidence suggests that GSH, UCP2
and SOCS-3 may attenuate ischemic injury in infected
mice by modifying microglia activity.
Despite a widely disseminated idea, only rare stud-
ies have shown that pre-existing infections can enhance
brain pathology in response to a subsequent new inﬂam-
matory process (Arsenijevic et al., 1998). In contrast,
several studies have shown that chronic infection can
attenuate some peripheral and central pathological pro-
cesses: complete Freund’s adjuvant prevents the onset
of experimental allergic encephalomyelitis (Bach, 2001),
schistosomiasis can protect against asthma (Yang et al.,
2007), coxsackievirus B3 can inhibit cardiomyopathy (Hu-
ber et al., 2006) and various infections can attenuate mu-
rine models of multiple sclerosis (Sewell et al., 2002). In
some conditions, a pre-existing inﬂammation can induce
brain neurodegeneration. This is the case for the acute
peripheral and/or central injection of LPS (Nguyen et al.,
2004; Cunningham et al., 2005; McColl et al., 2007; Qin et
al., 2007; Spencer et al., 2007). However, it appears that
the LPS dose used in these models may be a determinant
in the observed degeneration. In fact, although high LPS
doses may increase cytokines and oxidative stress, low
doses of peripheral LPS have a neuroprotective effect
(Bordet et al., 2000). This is consistent with our recent
study in which we observed an increase in brain NGF and
8
ht
tp
://
do
c.
re
ro
.c
h
GSH levels 3 days after peripheral LPS treatment (Ar-
senijevic et al., 2007b; Hernadfalvi et al., 2007). In this
context, the present study provides a new model to
explore the effect of a pre-existing chronic inﬂammatory
status on the outcome of brain ischemic insult. Since
each bacterium or parasite produces different cytokine
and leukocyte activation proﬁles and, ultimately, pat-
terns of neurodegeneration, it is crucial to investigate
the molecular mechanisms surrounding the beneﬁcial or
deleterious effect of various models of chronic inﬂam-
mation on cerebral ischemia.
CONCLUSION
This study revealed a marked resistance of Toxoplasma
gondii–infected mice to acute cerebral ischemia that is
characterized by a decreased lesion size 1 day, 4 days and
14 days post-MCAO. Marked differences in pre- and/or
post-ischemic cytokines and antioxidant molecules could
explain this phenomenon. In addition, our ﬁndings imply
that GSH may play a pivotal role in these processes since
pharmacological depletion of GSH resulted in increased
lesion size and increased brain IFN levels. Functional
neurological data could be useful to conﬁrm further the
protective effect of Toxoplasma gondii infection on the
outcome of cerebral ischemia.
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